Evidence map›Paper›PMID 20927568›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2011

Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function.

Zhekang Ying, Thomas Kampfrath, Qinghua Sun, Sampath Parthasarathy, Sanjay Rajagopalan

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03788759 (Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03788759 phase2 / phase3completednot on this mapstarted 2019, after this paper: background citation

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorNucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do CearaRan2019 to 2021Enrolled48ConditionsSchizophrenia, Oxidative StressArmsAlpha-lipoic acid, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Dietary supplements for polycystic ovary syndrome.Journal of preventive medicine and hygiene · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhekang YingDavis Heart and Lung Research Institute, Colleges of Medicine and Public Health, The Ohio State University, Room 110, 473W 12th Avenue, Columbus, OH 43210-1252, USA.
Thomas Kampfrath
Qinghua Sun
Sampath Parthasarathy
Sanjay Rajagopalan
The Ohio State University · US

Funding

Air Pollution and Hypertension: Vascular MechanismsR01ES015146 · NIEHS · UNIVERSITY OF MARYLAND BALTIMORE · PI RAJAGOPALAN, SANJAY · 2007 to 2018
$4.5M
Hypothalamic Inflammation and PM2.5 Exposure-Induced Insulin ResistanceR01ES024516 · NIEHS · UNIVERSITY OF MARYLAND BALTIMORE · PI YING, ZHEKANG · 2014 to 2018
$1.5M
Air Pollution Exposure/Atherosclerosis:Vascular MechanismR01ES013406 · NIEHS · OHIO STATE UNIVERSITY · PI RAJAGOPALAN, SANJAY · 2004 to 2007
$1.3M
NIEHS NIH HHS R01 ES013406NIEHS NIH HHS R01ES013406NIEHS NIH HHS R01 ES015146NIEHS NIH HHS R01ES015146NIEHS NIH HHS R01 ES024516
6 · The paper itself

Abstract

objectiveα-Lipoic acid (LA) exerts beneficial effects in cardiovascular diseases though its antioxidant and/or anti-inflammatory functions. It is postulated that the anti-inflammatory function of LA results from its antioxidant function. In this study we tested whether inhibition of NF-κB by LA is dependent on its antioxidant function.

methodsHuman umbilical vein endothelial cells (HUVECs) were treated with tumor necrosis factor-α (TNFα) in the presence of various antioxidants, including LA, tiron, apocynin, and tempol. The activation of the nuclear factor-κB (NF-κB) signaling pathway was then analyzed.

resultsLA, but not other tested antioxidants, inhibited TNFα-induced inhibitor-kappaB-α (IκBα) degradation and VCAM-1 and COX2 expression in HUVECs. Although LA activated the phosphatidylinositol-3-kinase (PI3-kinase)/Akt pathway in HUVECs, inhibition of Akt by LY294002 did not affect inhibition of TNFα-induced IκBα degradation by LA. In transient co-transfection assays of a constitutively active mutant of IκB kinase-2 (IKK2), IKK2(EE), and a NF-κB luciferase reporter construct, LA dose-dependently inhibited IKK2(EE)-induced NF-κB activation in addition to inhibiting IKK activity in in vitro assays. Consistent with the effect on luciferase expression, LA inhibited IKK2(EE)-induced cyclo-oxygenase-2 (COX2) expression, suggesting that IKK2 inhibition by LA may be a relevant mechanism that explains its anti-inflammatory effects.

conclusionsLA inhibits NF-κB activation through antioxidant-independent and probably IKK-dependent mechanisms.

Indexed as

AnimalsAntioxidantsCells, CulturedCyclooxygenase 2Endothelial CellsEndothelium, VascularHumansNF-kappa BProto-Oncogene Proteins c-aktThioctic AcidTumor Necrosis Factor-alphaUmbilical VeinsAntioxidantsCyclooxygenase 2NF-kappa BProto-Oncogene Proteins c-aktThioctic AcidTumor Necrosis Factor-alpha

Identifiers

PMID20927568
PMCPMC5832356
OpenAlexW1987258998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.